KR101769634B1 - 재조합 ａｄａｍｔｓ13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물 - Google Patents

재조합 ａｄａｍｔｓ13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물 Download PDF

Info

Publication number
KR101769634B1
KR101769634B1 KR1020127004995A KR20127004995A KR101769634B1 KR 101769634 B1 KR101769634 B1 KR 101769634B1 KR 1020127004995 A KR1020127004995 A KR 1020127004995A KR 20127004995 A KR20127004995 A KR 20127004995A KR 101769634 B1 KR101769634 B1 KR 101769634B1
Authority
KR
South Korea
Prior art keywords
adamts13
protein
cation exchange
buffer
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127004995A
Other languages
English (en)
Korean (ko)
Other versions
KR20120053013A (ko
Inventor
마인하르트 하슬라허
아르투르 미테러
크리스티안 피에들러
크리스타 마이어
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20120053013A publication Critical patent/KR20120053013A/ko
Application granted granted Critical
Publication of KR101769634B1 publication Critical patent/KR101769634B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127004995A 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물 Active KR101769634B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
US61/230,308 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022447A Division KR101883610B1 (ko) 2009-07-31 2010-08-02 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물

Publications (2)

Publication Number Publication Date
KR20120053013A KR20120053013A (ko) 2012-05-24
KR101769634B1 true KR101769634B1 (ko) 2017-08-18

Family

ID=42588355

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020207036716A Ceased KR20200146042A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020237042089A Ceased KR20230170815A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020227016072A Ceased KR20220066435A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020127004995A Active KR101769634B1 (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020197031048A Ceased KR20190122272A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020187021317A Ceased KR20180087463A (ko) 2009-07-31 2010-08-02 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020177022447A Active KR101883610B1 (ko) 2009-07-31 2010-08-02 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020207036716A Ceased KR20200146042A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020237042089A Ceased KR20230170815A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020227016072A Ceased KR20220066435A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197031048A Ceased KR20190122272A (ko) 2009-07-31 2010-08-02 재조합 ａｄａｍｔｓ１３ 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020187021317A Ceased KR20180087463A (ko) 2009-07-31 2010-08-02 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
KR1020177022447A Active KR101883610B1 (ko) 2009-07-31 2010-08-02 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물

Country Status (22)

Country Link
US (3) US8945895B2 (enExample)
EP (3) EP2459715B1 (enExample)
JP (6) JP5907869B2 (enExample)
KR (7) KR20200146042A (enExample)
CN (3) CN107267490A (enExample)
AU (1) AU2010277491B2 (enExample)
CA (2) CA2916508A1 (enExample)
CO (1) CO6612194A2 (enExample)
DK (1) DK2459715T3 (enExample)
EA (3) EA023783B1 (enExample)
ES (3) ES3039686T3 (enExample)
HR (1) HRP20192303T1 (enExample)
HU (1) HUE046909T2 (enExample)
IN (1) IN2012DN00907A (enExample)
LT (1) LT2459715T (enExample)
MX (2) MX348178B (enExample)
NZ (2) NZ620988A (enExample)
PL (2) PL3211077T3 (enExample)
PT (1) PT2459715T (enExample)
SG (2) SG193855A1 (enExample)
SI (1) SI2459715T1 (enExample)
WO (1) WO2011012726A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
WO2012125626A2 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
BR112014031842B1 (pt) * 2012-06-21 2020-09-15 Baxalta GmbH Método para remover um contaminante viral de uma preparação
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN116159130B (zh) 2016-08-04 2025-09-09 武田药品工业株式会社 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US20210024573A1 (en) * 2018-04-03 2021-01-28 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
JP7568638B2 (ja) * 2019-04-03 2024-10-16 ジェンザイム・コーポレーション 組換えタンパク質の連続的生産
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
KR20240154657A (ko) 2022-03-07 2024-10-25 다케다 야쿠힌 고교 가부시키가이샤 임상 인간 igg 제품의 친화도 크로마토그래피 생산
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
EP4523680A1 (en) * 2022-05-10 2025-03-19 Green Cross Corporation Novel liquid formulation for plasma protein
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246589A1 (en) * 2001-08-16 2006-11-02 David Ginsburg ADAMTS13 genes and proteins and variants, and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0629135B1 (en) 1992-03-02 2000-07-26 Bioeng, Inc. Viral inactivation method
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4707231B2 (ja) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
WO2002031163A1 (en) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
IL158297A0 (en) * 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
MXPA04006053A (es) 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
JP3983260B2 (ja) 2003-07-09 2007-09-26 塩野義製薬株式会社 アトピー性皮膚炎誘引物質
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US20080138790A1 (en) * 2004-04-13 2008-06-12 Winslow Robert M Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
CA2592888A1 (en) * 2005-01-05 2006-07-13 Foundation For Fatal Rare Diseases Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
CA2606351C (en) 2005-06-17 2016-12-13 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
EP1968999A2 (en) * 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
ES2386574T3 (es) 2006-02-16 2012-08-23 Mitsubishi Chemical Medience Corporation Procedimiento de detección de afección en paciente con alteración de la consciencia
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
EP2374878B1 (en) * 2007-06-22 2015-08-19 The Chemo-Sero-Therapeutic Research Institute Novel adamts-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
KR101293504B1 (ko) 2007-07-11 2013-08-07 노보 노르디스크 에이/에스 혼합형 또는 다중형 수지를 사용하는 인자 ｖⅰⅰⅰ의 정제
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246589A1 (en) * 2001-08-16 2006-11-02 David Ginsburg ADAMTS13 genes and proteins and variants, and uses thereof

Also Published As

Publication number Publication date
ES2763207T3 (es) 2020-05-27
MX348178B (es) 2017-05-29
US11661593B2 (en) 2023-05-30
SI2459715T1 (sl) 2020-01-31
JP6216930B2 (ja) 2017-10-25
US12492390B2 (en) 2025-12-09
NZ597756A (en) 2014-03-28
KR20190122272A (ko) 2019-10-29
LT2459715T (lt) 2020-01-10
KR20220066435A (ko) 2022-05-24
AU2010277491A2 (en) 2012-06-21
PL2459715T3 (pl) 2020-04-30
EP3211077A1 (en) 2017-08-30
JP5907869B2 (ja) 2016-04-26
EA023783B1 (ru) 2016-07-29
ES3000382T3 (en) 2025-02-28
HUE046909T2 (hu) 2020-04-28
PT2459715T (pt) 2020-01-09
EP2459715A2 (en) 2012-06-06
EP4299735B1 (en) 2025-05-21
WO2011012726A2 (en) 2011-02-03
HRP20192303T1 (hr) 2020-10-02
ES3039686T3 (en) 2025-10-23
KR20170096061A (ko) 2017-08-23
CN107988192A (zh) 2018-05-04
KR20120053013A (ko) 2012-05-24
SG178175A1 (en) 2012-03-29
EA201500952A1 (ru) 2016-05-31
KR20200146042A (ko) 2020-12-31
JP2022171925A (ja) 2022-11-11
EP4299735A2 (en) 2024-01-03
KR101883610B1 (ko) 2018-07-30
KR20230170815A (ko) 2023-12-19
CA2916508A1 (en) 2011-02-03
US20230242897A1 (en) 2023-08-03
EA201270214A1 (ru) 2012-08-30
IN2012DN00907A (enExample) 2015-04-03
CO6612194A2 (es) 2013-02-01
CN102482660A (zh) 2012-05-30
US8945895B2 (en) 2015-02-03
CN107267490A (zh) 2017-10-20
EA034292B1 (ru) 2020-01-24
SG193855A1 (en) 2013-10-30
PL3211077T3 (pl) 2025-04-14
WO2011012726A3 (en) 2011-03-31
NZ620988A (en) 2015-07-31
KR20180087463A (ko) 2018-08-01
EP3211077B1 (en) 2024-09-25
CA2769362A1 (en) 2011-02-03
US20110081700A1 (en) 2011-04-07
EA201992487A1 (ru) 2020-05-31
AU2010277491B2 (en) 2015-12-17
EP2459715B1 (en) 2019-10-02
US20150104849A1 (en) 2015-04-16
JP2021004265A (ja) 2021-01-14
BR112012002140A2 (pt) 2015-09-15
JP2015147815A (ja) 2015-08-20
JP2018203781A (ja) 2018-12-27
AU2010277491A1 (en) 2012-02-16
EP4299735A3 (en) 2024-04-24
MX2012001263A (es) 2012-05-22
JP2016222724A (ja) 2016-12-28
JP2013500711A (ja) 2013-01-10
DK2459715T3 (da) 2020-01-06

Similar Documents

Publication Publication Date Title
KR101769634B1 (ko) 재조합 ａｄａｍｔｓ13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
AU2021200815B2 (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK40103492B (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK40103492A (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1241929B (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1241929A1 (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1171784B (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
HK1171784A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
EA049036B1 (ru) Способы очистки рекомбинантного adamts13 и других белков и их композиции
BR112012002140B1 (pt) Método para purificar uma proteína tipo-desintegrina e metalopeptidase com trombospondina tipo 1 motivo 13 (adamts13) recombinante de uma amostra compreendendo proteína adamts13 e impurezas não adamts13

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9